Michael Wekerle announced an increase in his holdings in Orion Digital Corp. to 12.38% of outstanding common shares, up from 10.53%. This increase resulted from acquiring an additional 441,900 shares for approximately C$627,845.20. Wekerle also corrected previous reports, stating his holdings after May 2026 purchases were 9.83%, not 10.13%. He holds these shares for investment purposes and may adjust his position based on market conditions.
Michael Wekerle's updated holdings in Orion Digital Corp provide context for readers. For those tracking technology stocks, here is Pluang's market snapshot as of Sep 16, 2026 02:41 WIB: out of 150 priced US tech stocks, 50 rose and 99 fell. Notable movers include RIOT at USD 19.64 with a -6.23% change, WULF at USD 14.55 down 5.95%, and FIVN at USD 33.55 up 5.67%.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
